Somatostatin receptor type 1, 3, and 5 (SSTR1/3/5)

Somatostatin receptor subtypes 1, 3, and 5 (SSTR1, SSTR3, SSTR5) are G protein-coupled receptors that serve as critical regulators of the endocrine system and cellular proliferation. These receptors are primarily expressed in the pituitary gland, pancreas, and various neuroendocrine tissues, where they mediate the inhibitory effects of somatostatin on hormone secretion, including growth hormone (GH), adrenocorticotropic hormone (ACTH), and insulin (UniProt P30872, P35346). SSTR3 is uniquely associated with the induction of apoptosis and the inhibition of the cell cycle, providing a mechanism for anti-neoplastic activity (UniProt P32745). In clinical oncology and endocrinology, these subtypes are key targets for second-generation somatostatin analogs like pasireotide, which offers a broader binding profile compared to SSTR2-specific agents like octreotide. This multi-receptor affinity is particularly effective in treating refractory acromegaly and Cushing's disease, where SSTR5 expression is dominant. However, the high affinity for SSTR5 also results in the suppression of insulin secretion, making hyperglycemia a significant therapeutic challenge and safety concern (Gadelha et al., 2013; StatPearls).

Other names

SSTR1SSTR3SSTR5Somatotropin release-inhibiting factor receptor 1Somatotropin release-inhibiting factor receptor 3Somatotropin release-inhibiting factor receptor 5SS1RSS3RSS5RSRIF-1SRIF-3SRIF-5

Agonism of SSTR1, SSTR3, and SSTR5 leads to the inhibition of adenylyl cyclase, reduction of intracellular cAMP levels, and modulation of potassium and calcium channels, which suppresses the secretion of hormones such as growth hormone, ACTH, and insulin (UniProt P30872, P35346; StatPearls).